Chandra Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 29-06-2024
- Paid Up Capital ₹ 1.80 M
as on 29-06-2024
- Company Age 26 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.50 M
as on 29-06-2024
- Revenue 20.74%
(FY 2022)
- Profit 67.05%
(FY 2022)
- Ebitda -20.12%
(FY 2022)
- Net Worth 29.51%
(FY 2022)
- Total Assets -22.51%
(FY 2022)
About Chandra Drugs
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.80 M.
The company currently has active open charges totaling ₹6.50 M.
Anil Jain, Sunita Jain, and Amit Jain serve as directors at the Company.
- CIN/LLPIN
U24232MP1998PTC012735
- Company No.
012735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Chandra Drugs Private Limited offer?
Chandra Drugs Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Health Supplement, Herbal Supplements, Herbal Capsules, Common Disease Medicines, Pharmaceutical Capsules, Salon, Spa Kits & Equipments, Shaving Accessories, Ayurvedic,Herbal Products & Medicine, Pain Balm & Ointments, Ointment.
Who are the key members and board of directors at Chandra Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita Jain  | Director | 31-Mar-1998 | Current |
| Anil Jain | Director | 31-Mar-1998 | Current |
| Amit Jain | Director | 16-Aug-2021 | Current |
Financial Performance of Chandra Drugs.
Chandra Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.74% increase. The company also saw a substantial improvement in profitability, with a 67.05% increase in profit. The company's net worth Soared by an impressive increase of 29.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chandra Drugs?
In 2022, Chandra Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 20 Jan 2022 | ₹4.10 M | Open |
Canara Bank Creation Date: 19 May 2014 | ₹2.00 M | Open |
Canara Bank Creation Date: 11 Jan 2014 | ₹0.40 M | Open |
How Many Employees Work at Chandra Drugs?
Unlock and access historical data on people associated with Chandra Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chandra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chandra Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
